Source: Medicines & Healthcare Products Regulatory Agency (GB) Revision Year: 2019 Publisher: Norgine Pharmaceuticals Limited, Norgine House, Widerwater Place, Moorhall Road, Harefield, Uxbridge, UB9 6NS, UK
Dantrium IV 20mg.
| Pharmaceutical Form |
|---|
|
Powder for solution for injection. |
Each vial contains 20mg dantrolene sodium.
For the full list of excipients, see 6.1.
| Active Ingredient | Description | |
|---|---|---|
| Dantrolene |
The receptor molecule for dantrolene has not been identified. Dantrolene inhibits the binding of ryanodine. Under some conditions, dantrolene will lower intra-sarcoplasmic calcium concentrations in the resting state. This may be more important in diseased muscle (e.g. In malignant hyperthermia in humans and swine stress syndrome) than in muscle with normal function. |
| List of Excipients |
|---|
|
Mannitol |
Type I glass vial with chlorobutyl rubber stopper with aluminium seal. Each vial is provided with a single-use filtration device. Supplied in packs of 12 or 36 vials.
Not all pack sizes may be marketed.
Norgine Pharmaceuticals Limited, Norgine House, Widerwater Place, Moorhall Road, Harefield, Uxbridge, UB9 6NS, UK
PL 20011/0034
14/02/1980
| Drug | Countries | |
|---|---|---|
| DANTRIUM | Australia, Canada, Estonia, France, Ireland, Japan, Malta, Netherlands, New Zealand, Romania, United Kingdom, United States, South Africa |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
